Holen Sie sich die Stockscreener-App
1.56
4.88%
-0.08
Handel nachbörslich:
1.65
0.09
+5.77%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.61
24-Stunden-Volumen:
363.01K
Relative Volume:
0.25
Marktkapitalisierung:
$88.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.70%
1M Leistung:
+254.55%
6M Leistung:
-38.82%
1J Leistung:
-26.07%
1-Tages-Spanne:
$1.47
$1.65
1-Wochen-Bereich:
$1.37
$1.8298
52-Wochen-Spanne:
$0.41
$4.44
Tuhura Biosciences Inc Stock (HURA) Company Profile
Firmenname
Tuhura Biosciences Inc
Sektor
Branche
Telefon
813-875-6600
Adresse
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.56 | 92.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-11-05 | Eingeleitet | Maxim Group | Buy |
Tuhura Biosciences Inc Aktie (HURA) Neueste Nachrichten
HURA Technical Analysis & ETF Price Forecast - Intellectia AI
TuHURA Biosciences stock gains after Nasdaq compliance - Investing.com India
Update Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
TuHURA Biosciences regains Nasdaq listing compliance - Investing.com
Cancer immunotherapy firm TuHURA keeps share price over $1 to satisfy Nasdaq - Stock Titan
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - Nasdaq
HURA.O Technical Analysis & Stock Price Forecast - Intellectia AI
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - MarketBeat
TuHura files IND for leukemia drug combination study By Investing.com - Investing.com India
TuHura files IND for leukemia drug combination study - Investing.com Australia
Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers - marketscreener.com
New TuHURA antibody aims to boost leukemia drug response - Stock Titan
Is TuHURA Biosciences Inc. a strong growth stockJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
HURA PE Ratio & Valuation, Is HURA Overvalued - Intellectia AI
HURA Should I Buy - Intellectia AI
Should I trade or invest in TuHURA Biosciences Inc.2025 Earnings Impact & Free Community Consensus Stock Picks - mfd.ru
Will TuHURA Biosciences Inc. (PL3) stock sustain bullish trend into 2025 - mfd.ru
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Malaysian Reserve
Will TuHURA Biosciences Inc. stock maintain dividend yieldWeekly Trend Recap & Risk Managed Investment Signals - mfd.ru
HURA Stock Strongly Rises on Early Morning Surge - timothysykes.com
Is TuHURA Biosciences Inc. stock cheap at current valuationWeekly Trend Summary & Breakout Confirmation Alerts - mfd.ru
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Market Review: How volatile is Draganfly Inc stockTrade Risk Assessment & Smart Swing Trading Alerts - baoquankhu1.vn
FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results - streetwisereports.com
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug By Investing.com - Investing.com South Africa
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - MEXC
TuHURA Receives FDA Orphan Drug Designation - Intellectia AI
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug - Investing.com
Quarterly Earnings: What dividend growth rate does TuHURA Biosciences Inc offer2025 Volume Leaders & Trade Opportunity Analysis - baoquankhu1.vn
TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice - TipRanks
TuHURA Biosciences Received Notice of Noncompliance - TradingView
Will TuHURA Biosciences Inc. outperform its industry peers2025 Volume Leaders & Safe Capital Investment Plans - mfd.ru
Risk Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Breakout Watch: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
TuHURA Biosciences (NASDAQ:HURA) Shares Up 0.5% – Here’s Why - Defense World
MACD Signal: Will TuHURA Biosciences Inc outperform its industry peers2025 Historical Comparison & Verified High Yield Trade Plans - baoquankhu1.vn
Will TuHURA Biosciences Inc. stock gain from lower inflation2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Will TuHURA Biosciences Inc. stock benefit from green energy trendsQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is TuHURA Biosciences Inc. stock supported by innovation pipelinePrice Action & Verified Momentum Stock Alerts - ulpravda.ru
HURA: Analyst Reiterates Buy Rating, Lowers Price Target | HURA Stock News - GuruFocus
Risk Hedge: Will TuHURA Biosciences Inc. (PL3) stock attract long term capital inflows - Улправда
Can TuHURA Biosciences Inc. (PL3) stock expand revenue streams2025 Historical Comparison & Weekly High Return Stock Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock is popular among millennialsTake Profit & AI Driven Stock Price Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock could see breakout soonMid Cap Growth Trends & Rapid Capital Gain - ulpravda.ru
TuHURA Biosciences Inc Stock Analysis and ForecastRetail Trading Trends & Enter Your Email to Get Stock Alerts - earlytimes.in
Tuhura Biosciences amends loan agreement, secures full $3M - MSN
Is TuHURA Biosciences Inc PL3 a good long term investmentStop Loss Placement Tips & Big Profit Small Investment - earlytimes.in
What the Latest News Means for ABS Marine Services Limited Stock InvestorsTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
TUHURA Biosciences announces $15.6M registered direct offering - MSN
What analysts say about TuHURA Biosciences Inc PL3 stockEvening Star Patterns & Don’t Miss These Undervalued Stocks - earlytimes.in
Finanzdaten der Tuhura Biosciences Inc-Aktie (HURA)
Es liegen keine Finanzdaten für Tuhura Biosciences Inc (HURA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):